Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Other Non-Current Liabilities (2023 - 2025)

Historic Other Non-Current Liabilities for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $3.7 million.

  • BioLineRx's Other Non-Current Liabilities fell 1555.56% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 1555.56%. This contributed to the annual value of $5.4 million for FY2024, which is 5502.01% down from last year.
  • Per BioLineRx's latest filing, its Other Non-Current Liabilities stood at $3.7 million for Q3 2025, which was down 1555.56% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Other Non-Current Liabilities registered a high of $15.4 million during Q2 2023, and its lowest value of $3.7 million during Q1 2025.
  • Over the past 3 years, BioLineRx's median Other Non-Current Liabilities value was $5.4 million (recorded in 2024), while the average stood at $7.7 million.
  • Within the past 5 years, the most significant YoY rise in BioLineRx's Other Non-Current Liabilities was 80.81% (2024), while the steepest drop was 7144.63% (2024).
  • Over the past 3 years, BioLineRx's Other Non-Current Liabilities (Quarter) stood at $11.9 million in 2023, then crashed by 55.02% to $5.4 million in 2024, then crashed by 31.32% to $3.7 million in 2025.
  • Its last three reported values are $3.7 million in Q3 2025, $4.4 million for Q2 2025, and $3.7 million during Q1 2025.